Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under new leadership, the company has focused on specific objectives, cut costs, and looked to maximize revenue opportunities. We believe the company is on a better and more sustainable track and are excited about ongoing developments and the just released 1Q2024 earnings report reinforces that view.